Skip to content
Evigrade
CriticalPotassium salt with systemic alkalinising effect, used for kidney stone prevention and hypokalaemia×Potassium-sparing diuretics (mineralocorticoid receptor antagonists)

Updated · Methodology

Mechanism

Spironolactone is a potassium-sparing diuretic: it competes with aldosterone for receptors in the distal tubule of the kidney, so the kidneys excrete more sodium and water but retain potassium (spironolactone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Potassium citrate is a potassium salt: one 1080 mg tablet contains 10 mEq, or 390 mg, of potassium (potassium citrate SmPC, AEMPS). Potassium citrate increases urinary potassium by about the amount it contains. When the kidneys cannot excrete potassium properly, it can cause hyperkalaemia and cardiac arrest (potassium citrate label, US Food and Drug Administration, FDA). With a potassium-sparing diuretic it can therefore cause severe hyperkalaemia (FDA). The spironolactone documents also describe severe hyperkalaemia when spironolactone is combined with potassium supplements (AEMPS, FDA).

Symptoms

Hyperkalaemia is usually asymptomatic and may show only as a raised serum potassium and characteristic changes on the electrocardiogram (ECG): peaked T waves, loss of P waves, ST segment depression and QT prolongation. Late signs are muscle paralysis and cardiac arrest. Life-threatening hyperkalaemia can develop rapidly (potassium citrate label, US Food and Drug Administration, FDA). When symptoms occur, they include heart rhythm disturbances, tingling and numbness (paraesthesia), muscle weakness, flaccid paralysis and muscle spasms (spironolactone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). In people with severe heart failure who receive spironolactone, hyperkalaemia can be fatal (spironolactone SmPC, AEMPS).

Management

The combination is contraindicated. The US potassium citrate label contraindicates potassium citrate in patients receiving potassium-sparing agents and names spironolactone (potassium citrate label, US Food and Drug Administration, FDA). The Spanish potassium citrate summary of product characteristics (SmPC) says potassium citrate must not be given to patients receiving potassium-sparing diuretics and also names spironolactone (potassium citrate SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The spironolactone SmPC, in turn, says to avoid combining spironolactone with potassium supplements (spironolactone SmPC, AEMPS). In heart failure, potassium supplements are generally stopped when spironolactone is started (spironolactone label, FDA). In severe heart failure, monitor potassium and creatinine one week after starting spironolactone or increasing its dose, then monthly for the first 3 months, every 3 months until the end of the first year and every 6 months thereafter. Interrupt or stop spironolactone if potassium exceeds 5 mmol/L or creatinine exceeds 4 mg/dL (AEMPS). During potassium citrate treatment, monitor electrolytes, creatinine and the complete blood count every 4 months, more often in heart or kidney disease or acidosis. Perform periodic electrocardiograms (ECGs), and stop potassium citrate if hyperkalaemia develops (FDA). In hyperkalaemia, stop potassium-containing medicines and potassium-sparing agents and monitor heart rhythm and electrolytes closely (FDA). The Spanish potassium citrate SmPC describes treatment of hyperkalaemia: intravenous 10% glucose with 10–12 units of insulin per 1000 mL, intravenous sodium bicarbonate for acidosis, and haemodialysis or peritoneal dialysis (AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Potassium citrate

Other interactions with Spironolactone